AVAI Bio and Ainnova Tech mutually terminate JV agreement as of May 7, 2026

AVAI BIO, INC.

No penalties incurred; all obligations and liabilities under the License Agreement (Nov 8, 2024) released.
Joint venture Ai-Nova Acquisition Corp. (AAC) to be formally dissolved per Nevada law.
Each party retains its own intellectual property; all cross-licenses revoked.
Both parties execute mutual releases of all claims arising from the JV.
Company states the termination reflects independent business strategies going forward.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AVAI BIO, INC. terminated Joint Venture and License Agreement with Ainnova Tech Inc. valued at No termination penalties or further financial obligations will be incurred by either party. (effective 2026-05-07).

Action: termination
Agreement: license
Counterparty: Ainnova Tech Inc.
Value: No termination penalties or further financial obligations will be incurred by either party.
Effective: 2026-05-07

Exact text from the filing

On May 7, 2026, Avai Bio, Inc., formerly known as Avant Technologies Inc. (the “Company” or “AVAI”), and Ainnova Tech Inc. (“Ainnova” or “AINN”) entered into a Mutual Termination Agreement (the “Termination Agreement”) to terminate, by mutual consent, the Joint Venture and License Agreement dated November 8, 2024 (effective as of November 11, 2024) (the “License Agreement”).

View on SEC.gov

Browse all material agreements →

AVAI BIO, INC. filing history →

Source: SEC EDGAR

accession 0001740797-26-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.